At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 18, 2026 at 16:30 ET
Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved the new 2026 Equity Incentive Plan, replacing the 2016 plan and adding 650,000 new shares plus the prior plan's available reserve and returning shares. The election of two Class I directors and the ratification of Ernst & Young as auditor were also approved. This is a routine governance filing that does not change the company's operational outlook or financial position.
- Stockholders approved the 2026 Equity Incentive Plan, adding 650,000 new shares plus the prior plan's available reserve and returning shares to the share reserve.
- Two Class I directors were elected: Dinesh V. Patel, Ph.D. (48,714,702 for) and Lewis T. Rusty Williams, M.D., Ph.D. (45,371,193 for).
- Stockholder approval was received for executive compensation (say-on-pay) and the appointment of Ernst & Young as independent registered public accounting firm.
- The 2026 Plan replaces the 2016 Equity Incentive Plan and allows for grants of options, SARs, restricted stock, RSUs, and other stock-based awards.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access